Covid-19 roundup: Synairgen turns to post-hoc analyses after failed drug trial; EU terminates Valneva vaccine contract
After halting enrollment in an NIH-led Phase II/III study, and failing an earlier Phase III trial, UK-based Synairgen’s Covid-19 drug did show some promise in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
